Aimeike (300896): High growth, high profits, and a rich pipeline of products under development

Incident The company released its 2023 annual report and 2024/1 quarterly report: 2023 revenue of 2,869 billion yuan (+48.0% year over year), net profit to mother of 1,888 billion yuan (+47.1% year over year), deducted from Africa

國聯證券15:56

Aimeike (300896): A steady start to 24Q1, good physical growth, and the release of recycled products

Core view Under a high base, the company started well. In 24Q1, revenue increased by 28.2% and +15.6% month-on-month, while net profit attributable to mother and net profit after deduction of 27.4% and 36.5% increased by 27.4% and 36.5%, which is at the top of the performance forecast range. which

中信建投證券14:26

China Post Securities released a research report on April 26 stating that it gave Aimeike (300896.SZ) a purchase rating. The main reasons for the rating include: 1) the high boom in the industry and high revenue growth from January to February '24; 2) gro

China Post Securities released a research report on April 26 stating that it gave Aimeike (300896.SZ) a purchase rating. The main reasons for the rating include: 1) the high boom in the industry and high revenue growth from January to February '24; 2) gross margin declined slightly, the cost ratio was optimized during the period, and the net interest rate remained high. (Mainichi Keizai Shimbun)

Zhitong Finance08:48

Aimeike (300896): Steady improvement of core products and orderly layout of new products to jointly build a performance moat

Investment highlights: The company released the 24Q1 financial report. The performance is in the middle of the forecast, in line with market expectations. According to the company announcement (same below), the 24Q1 company's revenue was 808 million yuan, an increase of 28.24% over the previous year; net profit to mother was 5.27

申萬宏源研究07:31

Cinda Securities released a research report on April 25 stating that it gave Aimeike (300896.SZ) a purchase rating. The main reasons for the rating include: 1) excellent revenue growth, significant rate optimization, and non-recurrent factors slightly dis

Cinda Securities released a research report on April 25 stating that it gave Aimeike (300896.SZ) a purchase rating. The main reasons for the rating include: 1) excellent revenue growth, significant rate optimization, and non-recurrent factors slightly disrupt net interest rates; 2) expecting to continue to provide revenue growth after new products are approved/gradually released. (Mainichi Keizai Shimbun)

Zhitong FinanceApr 25 19:27

The quarterly report verifies the strong growth in performance, why is Aimeike (300896.SZ) making strong players stronger?

In recent years, with the improvement of living standards, people have begun to pursue a higher level of spiritual life, and the face value economy has made great strides. According to a report published by Tencent Marketing Insights, the Chinese medical beauty market has grown at a compound annual growth rate of 17.5% since 2017 to nearly 190 billion dollars in 2021. However, due to multiple factors such as changes in residents' income expectations, the growth rate of medical and aesthetic consumption began to slow in 2022. The Zhitong Finance App notes that under the pessimistic expectations of the market, medicine and beauty have been questioned a lot over the past year or so as an “improved” optional consumption.

Zhitong FinanceApr 25 17:45